Immunic (NASDAQ:IMUX) Research Coverage Started at Guggenheim
Guggenheim assumed coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $7.00 price target on the stock. Several other brokerages also recently weighed in on IMUX. upgraded shares of Immunic to a “strong-buy” rating in a research note on […]
27 Mar 05:16 · The Markets Daily